logo

For the Inventor, By the Inventor

Memphis, TN, United States of America

Gtx Corporation


USPTO Granted Patents = 55

% Expired Patents = 29.1



Trademarks = 4

Forward Citations = 931

Loading Chart...
Loading Chart...

51 inventors (with patents filed for the assignee):

goldMedal James T Dalton (33 out of 102 patents)

silverMedal Ramesh Narayanan (18 out of 43 patents)

bronzeMedal Duane Douglas Miller (18 out of 119 patents)

4.  Mitchell S Steiner (12 out of 40 patents)

5.  Sunjoo Ahn (10 out of 21 patents)

6.  Patrick E Bertagna (9 out of 29 patents)

7.  Charles B Duke (9 out of 13 patents)

8.  Christopher C Coss (8 out of 12 patents)

9.  Thamarai Ponnusamy (7 out of 28 patents)

10.  Dong-Jin Hwang (7 out of 23 patents)

11.  Yali He (7 out of 32 patents)

12.  Seoung-Soo Hong (6 out of 10 patents)

13.  Wei Li (6 out of 15 patents)

14.  Andrew Hamish Duncan (4 out of 7 patents)

15.  Li Wang (4 out of 7 patents)


Core Competencies:
Selective Androgen Receptor Modulators
Cancer Treatment
Tracking Device
Footwear Insole
Estrogen Receptor Ligands
Nuclear Receptor Binding Agents
GPS Technology
Prodrugs
Image Processing
Metabolites
Solid Forms

55 patents:

1. 11272761 - System and method for embedding a tracking device in a footwear insole (2022-03-15),
2. 10743615 - System and method for embedding a tracking device in a footwear insole (2020-08-18),
3. 10441570 - Selective androgen receptor degrader (SARD) Ligands and methods of use thereof (2019-10-15),
4. 10314807 - Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) (2019-06-11),
5. 10301285 - Compounds for treatment of cancer (2019-05-28),
6. 10292453 - System and method for embedding a tracking device in a footwear insole (2019-05-21),
7. 10258596 - Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) (2019-04-16),
8. 10155728 - Compounds for treatment of cancer (2018-12-18),
9. 10093613 - Selective androgen receptor degrader (SARD) ligands and methods of use thereof (2018-10-09),
10. 10035763 - Selective androgen receptor degrader (SARD) ligands and methods of use thereof (2018-07-31),
11. 10017471 - Selective androgen receptor degrader (SARD) ligands and methods of use thereof (2018-07-10),
12. 9981915 - Compounds for treatment of cancer (2018-05-29),
13. 9969683 - Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) (2018-05-15),
14. 9910862 - System and method for processing location data (2018-03-06),
15. 9854872 - System and method for embedding a tracking device in a footwear insole (2018-01-02),
Gtx Corporation, based in Memphis, TN, specializes in the development of innovative technologies primarily focused on Selective Androgen Receptor Modulators (SARMs) and their applications in cancer treatment. The company also explores advancements in tracking devices, footwear insoles, and various receptor binding agents, including estrogen receptor ligands. With a commitment to enhancing therapeutic options and integrating GPS technology, Gtx Corporation aims to address significant health challenges and improve quality of life through its diverse technological portfolio.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Gtx Corporation
55 Patents

#17 in Memphis, TN

#59 in Tennessee

#6,444 in US

#12,894 in the World

Memphis, TN (US)
Memphis, TN, United States of America

Gtx Corporation

Forward Citations = 931

51 inventors:

goldMedal James T Dalton (33 out of 102 patents)

silverMedal Ramesh Narayanan (18 out of 43 patents)

bronzeMedal Duane Douglas Miller (18 out of 119 patents)

4.  Mitchell S Steiner (12 out of 40 patents)

5.  Sunjoo Ahn (10 out of 21 patents)

Please report any incorrect information to [email protected]
Loading…